| Literature DB >> 15863203 |
Rosangela Invernizzi1, Erica Travaglino, Mara De Amici, Silvia Brugnatelli, Isabella Ramajoli, Bianca Rovati, Chiara Benatti, Edoardo Ascari.
Abstract
We treated with thalidomide seven patients with primary MDS and observed reduction of the transfusion requirement in three cases and reduction of bone marrow blasts in one case. The apoptotic rate of bone marrow cells diminished significantly from a mean of 43.8% to a mean of 17.5%, whereas the proliferative activity did not change. Plasma TNF-alpha, bFGF, IL-1beta levels decreased variably, whereas VEGF levels tended to increase. Matrix metalloproteinases 2 and 9 expression decreased in bone marrow cells of responders. A reduction of CD4 cells and an increase of NK cells was observed in the peripheral blood. Thus, thalidomide may produce a fairly good hematological improvement in erythroid series in MDS, with complex biological mechanisms.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15863203 DOI： 10.1016/j.leukres.2004.11.008
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156